drugset
drugset / Trial / NCT06929624

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

NCT06929624 ↗

Phase 3 Recruiting 280 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.

Timeline

Start
2025-04-24
Primary completion
2027-03
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-A1912 Unknown — —
Background Gemcitabine Small molecule — —
Background Oxaliplatin Small molecule — —
Background Rituximab Monoclonal antibody — —

Indications

diffuse large B-cell lymphoma